The particularities of hemostasis in patients with non-ST elevation myocardial infarction and some comorbidities

The formation of an obstructive thrombus within artery remains a major cause mortality and morbidity worldwide. [1] Despite effective inhibition platelet function by modern antiplatelet therapies, these agents fail to fully eliminate atherothrombotic risk. This may well be related extensive vascular disease, beyond the protective abilities treatment used. However, recent evidence suggests that residual risk in those treated with therapies is related, at least part, impaired fibrin clot lysis. Along lines, thrombosis result several changes local homeostasis: endothelial dysfunction, fibrinolytic system, increased content some coagulation factors, decreased natural inhibitors, hyperactivity [2] [3]. In this review, we attempt shed more light on role hypofibrinolysis predisposition arterial events. We provide brief overview system followed addressing coagulation, anticoagulation, fibrinolysis acute conditions, including coronary disease. also discuss prognostic implications biomarkers regarding thrombotic events, addressing, particular, people who are exposed metabolic risks (hyperlipidemia, hypertension, diabetes). conclude affecting appears contribute individuals disease therapy, targeting proteins coagulant represents viable strategy improve outcomes population. Future work required refine antithrombotic approach modulating pathological abnormalities anticoagulant tailoring therapy according need each individual